Scattergram comparing 3,598 Enterococcus spp. surveillance isolates (obtained from 2011 to 2013) tested against oritavancin and vancomycin. Breakpoint concentrations for vancomycin (solid vertical lines) were compared to the oritavancin breakpoint (≤0.12 μg/ml for vancomycin-susceptible E. faecalis; broken horizontal line) assigned by the FDA and/or proposed elsewhere based on ECOFF and PK/PD analyses (8, 15–17, 19, 27). A total of 12 and 746 isolates had intermediate susceptibility or resistance to vancomycin, and of those isolates, 93.3% were inhibited by 0.12 μg/ml oritavancin, e.g., they were oritavancin susceptible.